Stock analysts at Leerink Swann initiated coverage on shares of Mylan (NASDAQ:MYL) in a research report issued to clients and investors on Tuesday, The Fly reports. The firm set a “market perform” rating on the stock.
Several other research firms have also weighed in on MYL. Citigroup set a $42.00 price objective on Mylan and gave the stock a “buy” rating in a research note on Wednesday, October 4th. Zacks Investment Research raised Mylan from a “strong sell” rating to a “hold” rating and set a $43.00 price objective for the company in a research note on Tuesday, October 10th. BidaskClub raised Mylan from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 7th. Guggenheim initiated coverage on Mylan in a research note on Tuesday, December 12th. They set a “buy” rating and a $59.00 price objective for the company. Finally, Instinet reissued a “buy” rating and set a $37.00 price objective on shares of Mylan in a research note on Thursday, October 5th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $42.78.
Shares of Mylan (NASDAQ:MYL) traded up $0.45 during mid-day trading on Tuesday, hitting $42.31. The stock had a trading volume of 4,335,300 shares, compared to its average volume of 6,012,526. Mylan has a one year low of $29.39 and a one year high of $45.87. The firm has a market cap of $22,700.00, a PE ratio of 25.49, a PEG ratio of 3.15 and a beta of 1.38. The company has a current ratio of 1.46, a quick ratio of 0.95 and a debt-to-equity ratio of 1.05.
Several institutional investors have recently bought and sold shares of the company. Greenlight Capital Inc. increased its stake in shares of Mylan by 0.4% in the third quarter. Greenlight Capital Inc. now owns 10,744,307 shares of the company’s stock worth $337,048,000 after purchasing an additional 42,600 shares during the period. Wealthsource Partners LLC increased its stake in Mylan by 57.6% during the third quarter. Wealthsource Partners LLC now owns 14,705 shares of the company’s stock valued at $461,000 after acquiring an additional 5,375 shares during the period. Americafirst Capital Management LLC bought a new position in Mylan during the third quarter valued at about $471,000. Cypress Capital Group increased its stake in Mylan by 37.7% during the third quarter. Cypress Capital Group now owns 13,079 shares of the company’s stock valued at $410,000 after acquiring an additional 3,579 shares during the period. Finally, California Public Employees Retirement System increased its stake in Mylan by 4.2% during the third quarter. California Public Employees Retirement System now owns 1,129,978 shares of the company’s stock valued at $35,447,000 after acquiring an additional 45,822 shares during the period. Institutional investors and hedge funds own 74.90% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking and Market News and is the property of of American Banking and Market News. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.americanbankingnews.com/2018/01/02/leerink-swann-begins-coverage-on-mylan-myl.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
